Previous 10 | Next 10 |
2023-05-04 07:16:41 ET Ironwood Pharmaceuticals press release ( NASDAQ: IRWD ): Q1 Non-GAAP EPS of $0.25 beats by $0.01 . Revenue of $104.06M (+6.7% Y/Y) beats by $3.46M . 2023 Guidance: U.S. LINZESS Net Sales Growth 3% to 5%, Total Revenue $420 t...
– LINZESS (Iinaclotide) EUTRx prescription demand growth increased 10% year-over-year; LINZESS U.S. net sales of $250 million, an increase of 8% year-over-year – – GAAP net income of $46 million and adjusted EBITDA of $60 million; ended Q1 2023 with $740 milli...
2023-05-03 13:44:38 ET Ironwood Pharmaceuticals ( NASDAQ: IRWD ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open. The consensus EPS Estimate is $0.24 (+14.3% Y/Y) and the consensus Revenue Estimate is $100.6M (+2.7% Y/Y). Over the ...
– Pivotal Phase III data will be spotlighted via an oral presentation – – Additional efficacy and safety data will be featured across four posters – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today th...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 4, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (...
2023-04-14 11:28:52 ET Summary Pharmaceuticals/biotechnology is the only subsector with good value and quality scores. Healthcare equipment is the most overvalued one. IXJ: A global alternative to XLV. 10 stocks cheaper than their peers in April. This monthly art...
2023-04-13 11:00:54 ET Ironwood Pharmaceuticals ( NASDAQ: IRWD ) rose 3.4% amid speculation about an activist investor in the gastro intestinal drug company. Gordon Haskett in a note on Thursday highlighted that Ironwood ( IRWD ) announced Tuesday that its COO Jason Ri...
2023-04-11 08:58:33 ET Ironwood Pharmaceuticals ( NASDAQ: IRWD ) said on Tuesday that COO Jason Rickard's last day in the company will be May 12. The company is set to eliminate the role of COO, and Rickard's responsibilities will be transferred to the other members ...
2023-03-16 06:31:14 ET Summary The pharma/biotech subsector is undervalued by 16% relative to 11-year averages. Healthcare equipment is the less attractive subsector regarding both valuation and quality. Fast facts on PBE, a biotechnology and genomics ETF. 10 stocks cheape...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that management will participate in the following investor conferences: Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 9:10 a.m. ET at the Boston Marriott Copley Place ...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-22 07:00:07 ET Mohit Bansal from Wells Fargo issued a price target of $14.00 for IRWD on 2024-05-22 05:13:00. The adjusted price target was set to $14.00. At the time of the announcement, IRWD was trading at $6.78. The overall price target consensus is at $16.00 ...